Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05482893 · ClinicalTrials.gov registry record · Phase 1
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
A Phase 1 study of Pancreatic Ductal Adenocarcinoma and Biliary Tract Cancer (BTC), sponsored by Phanes Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 258
- Enrollment target
- 11
- Study locations
NCT05482893: Recruiting Phase 1 study of Pancreatic Ductal Adenocarcinoma and Biliary Tract Cancer (BTC), sponsored by Phanes Therapeutics.
NCT05482893 is a Phase 1 study of Pancreatic Ductal Adenocarcinoma and Biliary Tract Cancer (BTC) that is actively recruiting participants, run by Phanes Therapeutics. The registered enrollment target is 258 participants, below the 598-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (57% lower). The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05482893, a Phase 1 study of Pancreatic Ductal Adenocarcinoma and Biliary Tract Cancer (BTC), is actively recruiting participants, sponsored by Phanes Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 258 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Spevatamig (PT886). Patients with the following tumor types will be eligible for screening: unresectable or metastatic gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, biliary tract carcinoma (BTC) and pancreatic ductal adenocarcinoma (PDAC).
Conditions Studied
Interventions
- DRUG Paclitaxel
- DRUG Gemcitabine
- DRUG Abraxane
- DRUG KEYTRUDA® (pembrolizumab)
- DRUG Spevatamig (PT886)
Study Locations (11)
California
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center) - Duarte
- USC Norris Comprehensive Cancer Center - Los Angeles
Colorado
- Sarah Cannon Research Institute (SCRI) - Denver
Iowa
- University of Iowa - Iowa City
Kentucky
- Norton Cancer Institute - Louisville
Massachusetts
- Dana-Farber Cancer Institute (DFCI) - Boston
North Carolina
- Duke Cancer Center - Durham
Pennsylvania
- University of Pittsburgh Medical Center (UPMC) - Pittsburgh
Texas
- MD Anderson Cancer Center, GI Medical Oncology Dept - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 258 participants |
| Start Date | 2023-03-15 |
| Est. Completion | 2028-04 |
| Phase | Phase 1 |
What NCT05482893 shows while recruiting
NCT05482893 is an interventional study that assigns participants to a tested intervention. The registered 258 participants enrollment target is mid-sized for trials with a published cap, below the 598-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (57% lower).
The record links to 3 conditions, with Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Paclitaxel is the first listed.
NCT05482893 lists 11 locations in 10 states (California, Colorado, Iowa).
Frequently Asked Questions
What is clinical trial NCT05482893 about?
NCT05482893 is a clinical study titled "Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)". This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Spevatamig (PT886). Patients with the following tumor types will be eligible for sc...
What is the current status of trial NCT05482893?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 258 participants. The study started on 2023-03-15. Estimated completion is 2028-04.
What conditions does trial NCT05482893 study?
This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC), Gastric or Gastroesophageal Junction Adenocarcinoma.
What interventions are being tested in trial NCT05482893?
The interventions under investigation include: Paclitaxel (DRUG), Gemcitabine (DRUG), Abraxane (DRUG), KEYTRUDA® (pembrolizumab) (DRUG), Spevatamig (PT886) (DRUG).
Who is sponsoring clinical trial NCT05482893?
This trial is sponsored by Phanes Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05482893 being conducted?
This trial has 11 study locations across California, Colorado, Iowa, Kentucky, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Ductal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05482893's enrollment target sits among peer trials
258 24th of 84 higher than 61 of 84 other Pancreatic Ductal Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Ductal Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
-
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RECRUITING · Phase 1
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03785288 · 258 participants · Phase 3
Vaginal Cuff Brachytherapy Fractionation Study
- NCT04643002 · 258 participants · Phase 1
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
- NCT04924322 · 258 participants · Phase 2
Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies
- NCT05043012 · 258 participants · NA
Diagnostic Performance Of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging Of Prostate With Flexible AIR Coil (DoNEMAC Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI